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1 
EXPLANATION OF THESIS FORMAT 
This thesis has been prepared in the alternative t hesis format, and 
contains two separate manus c ripts . Each paper is complete in itself , 
with an abstract, introduction, materials and methods , results , 
discussion, acknowledgements and literature cited. The first paper 
discusses the production of monoclonal antibodies using Mycoplasma 
pulmonis naturally infected animals . The second paper deals with the 
identification of the tl..,_ pulmonis hemolysin . A current review of 
relevant literature to this thesis is included in the introduction. A 
summary and discussion is included after the manuscripts . 
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GENERAL INTRODUCTION 
Murine respiratory mycoplasmosis (MRM), a clinically silent disease 
indigenous to most conventional and barrier-maintained rodent colonies 
(25), results from a chronic infection of respiratory tissues by 
Mycoplasma pulmonis. The pathology of the disease has been well 
characterized (18,22), but mechanisms of virulence or virulence factors 
have not been identified . The goal of the research presented was to 
identify and partially characterize a membrane-bound hemolysin believed 
to be associated with pathogenesis. 
To provide the reader with background material relevant to these 
studies, three distinct areas will be discussed. The first area will 
include general characteristics of mycoplasmas, a description of tL 
pulmonis and the pathogenesis of MRM. Next, membrane antigens and 
activities of other mycoplasma species will be discussed in hopes of 
facilitating present and future studies with tL pulmonis. The third 
discussion area will be a brief general overview of hemolysins from 
bacteria, including a description and potential mechanisms of action of 
the tL pulmonis hemolysin . 
Mycoplasmas 
General Characteristics 
Mycoplasmas, which include approximately 50 different species, are 
the smallest and simplest self-replicating form of Eubacteria (66) and 
have been shown to colonize and infect animals, insects and plants. In 
animals, the resulting diseases are usually respiratory or urogenital in 
nature, but other areas of colonization have been well documented. The 
following discussion is based upon those species which have animal hosts, 
although other species have similar characteristics. 
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Mycoplasmas contain only a minimal set of organizational units 
essential for cell growth and replication: a plasma membrane to separate 
the cytoplasm from the external environment; ribosomes to assemble cell 
proteins; and a chromosome to provide the information for protein 
synthesis (66). The genome is typically 5 x 108 daltons in size, with a 
guanine:cytosine ratio in the range of 24-35 mole per cent (56,65). The 
coding capacity is believed to encode less than 700 different proteins, 
an insufficient number to supply all metabolic pathways needs (49,56). 
Thus, some macromolecule precursors must be provided by the environment, 
host tissues , or the growth medium . For instance, all mycoplasmas lack 
the orotic acid pathway for pyrimidine synthesis and the enzymatic 
pathways for de novo synthesis of purine bases (67). Pyrimidine and 
purine phosphorylases are present however, allowing conversion of 
nucleotide phosphates to the corresponding free base (66). Nucleotide 
phosphates or host DNA may be provided by the action of a membrane-
associated nuclease (51). Once obtained, the nucleotide bases are 
readily incorporated into the genome. 
In addition, mycoplasmas require exogenous phospholipids and 
cholesterol for plasma membrane synthesis. These organisms are either 
partially or totally incapable of synthesizing long chain fatty acids 
(73). This results in an inability to regulate membrane fluidity by 
preferential fatty acid synthesis or incorporation, the mechanism used by 
most bacteria. In mycoplasmas, membrane fluidity is influenced by the 
composition of the incorporated fatty acids (73) and is maintained and 
regulated by the incorporation of cholesterol (66). The cholesterol 
usually remains unaltered once incorporated. 
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Mycoplasmas contain a truncated respiratory system, located in the 
cytoplasmic fraction of the cell (66), and are unable to produce ATP via 
oxidative phosphorylation. They lack quinones and cytochromes, 
components of the electron transport system (ETS), leaving only two 
proven means of ATP production . In fermentative mycoplasmas, ATP is 
formed during glycolysis, whereas in nonfermentative mycoplasmas, the 
arginine dihydrolase pathway has been proposed as the major source of ATP 
(72). 
In general, mycoplasma replicat i on and protein synthesis resembles 
typical prokaryotic mechanisms. The mycoplasma DNA polymerase possesses 
the catalytic properties found in procaryotic DNA polymerase I, but lacks 
all exo- and endo- DNase activities (5 6 ). In addition, the ribosomes from 
my coplasmas have sedimentation coeffici ents , RNA/ proteins ratios and 
ribosomal RNA species similar to other prokaryotes . The major difference 
is that the rRNA species h ave a much lower quanine :cytosine content (43 -
48X) (65). The transfer RNAs, like the ribosomal RNAs, also resemble the 
corresponding transfer RNAs from other prokaryotes . The mycoplasmas, 
however, appear to contain fewer isoaccepting transfe r RNA species and 
less modified nucleotides, probably reflecting the limite d biosynthetic 
ability imposed by the small genome size (65). 
Mycoplasma pulmonis 
M..... pulmonis colonizes mice a nd rats , and has been reported to be 
found in most, if not all, rodent colonies in the United States (25). It 
has the general characteristics and nutrient requirements as described 
above. There have been five membrane-associated act i vi ties identified in 
vitro: lymphocyte mitogenesis , hemadsorpt i on, hemagglutination , 
hemolysis and a nuclease activity (3 6 ,51-54). Of these, hemadsorption 
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and hydrogen peroxide-mediated hemolysis appear to have no role in the 
virulence of M. pulmonis (33b). The others have not been characterized 
as to their role in pathogenesis, although it has been postulated that 
they may be involved (51,52). 
Pathogenesis of Murine Respiratory Mycoplasmosis (MRM) 
MRM has been extensively reviewed in recent years (18,20,22, 
23,26,27). This disease is often slow in onset and of relatively long 
duration. Several weeks or months are usually required for visible 
symptoms to develop. Offspring of infected mothers may acquire tL.. 
pulmonis in utero (18) or b y aerosol transmission in the first few weeks 
of life ( 18 ). Once infected , the animals serve as reservoirs of 
infection, transmitting the organism to cagemates and to adjacent cages 
(9). 
After transmission, tL.. pulmonis quickly overcomes the defense 
mechanisms of the host and tightly adheres to the surface of epithelial 
cells, particularly in the nasal passages and middle ear (18). The tight 
adherence to epithelial cells, often in a continuous blanket 3-5 
organisms thick (62), is mediated by a generalized interaction of the 
mycoplasmal membrane with the host cell membrane. Once attached , tL.. 
pulmonis directly injures the epithelial layers and stimulates an immune 
response. Common types of pathology are ciliostasis , loss of cilia, 
distention of intracellular spaces, cytoplasmic vacuolization, disruption 
of mitochondria, epithelial hyperplasia , metaplasia and syncytial giant 
cell formation (18). These changes are most likely due to the 
mycoplasmas utilizing host cellular components and the release of toxic 
metabolic wastes . Indirect injury a lso occurs to the cells through 
prolonged chemotaxis of neutrophils, the release of lymphokines, and the 
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release of large amounts of h y drolytic enzymes from mouse macrophages 
( 18). 
The principal lesions resulting from direct a nd indirect cellular 
injury are acute and chronic rhinitis, otitis media, laryngotr acheitis 
and bronchopnewnonia, all of which are characterized microscopically b y 
lymphoid hyperplasia , neutrophilic exudate a nd chronic inflammation (22). 
These observations suggest that the lesions are partially the resul t of 
ineffectual immune response in the host . In advanced cases of the 
disease, entire lung lobes can be afflicted with l esions. 
Eve n with severe lung epithelial injury , the disease often remains 
clinically silent until the terminal stages of the disease (48a). Most 
common clinical manifestations are snuffling and r a l es, which can be 
heard better than seen. Other s ymptoms are frequent rubbing of the eyes 
and, less frequently, head tilt due to labyrinthitis . Terminal stages of 
the disease often demonstrate weight loss, roughened hair coat, nasal and 
ocular discharges and dyspnea (48a) . Once c linical signs appear, the 
disease may s eem to spread through t h e colony r apidl y (62). 
One of the most noteworthy features of the disease is the lack of 
uniformity between the lesions in the l ungs and the severity of the 
infection, even in animals from the same cages ( 18). This has been 
a ttributed to environmental and genetic influences. In s tudies with rat 
colonies, it was demonstrated that the prevalence of pnewnonia increased 
directly with the environmenta l concentration of ammonia ( 16), and that 
the l evels of v itamins A and E (18) influenced the disease . In addition, 
prior infections with Sendai virus enhanced the growth of tl.,_ pulmonis and 
the severity of lung lesions in mice (18). The disease seems to progress 
more rapidly in older animals (44). Compar ison of animals matched for 
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age, sex and microbial and environmental factors, indicates that heredity 
is probably one of the most critical determinant for susceptibility to 
the disease (18). 
The prevalence of MRM in rodent colonies is puzzling in view of the 
fact that rodents respond immunologically, both locally and systemically, 
to infection with M..,_ pulmonis. In the local response, the submucosa of 
the respiratory tract and the lung parenchyma are rapidly infiltrated by 
lymphoid cells which differentiate into plasma cells secreting all of the 
major classes of antibodies (22). T lymphocytes are essential for this 
response and may limit dissemination of the mycoplasmas (22). System-
ically, spleen cells are activated and antibodies are released into the 
blood system (18) . In many cases, the immune response generated in one 
animal is able to protect an immunized , uninfected animal from severe 
disease, but not colonization, during a challenge infection. The 
mechanism of protection differs though between rats and mice. Mice are 
sufficiently protected with immune serum (75), whereas rats require 
immune spleen cells (13). 
Survival of !:L.. pulmonis in the presence of a strong immune response 
has several explanations. The intimate association of !:L.. pulmonis with 
the host cell surface and the ability of mycoplasmas to bind exogenous 
proteins readily (34,68) suggests that the organisms might avoid the 
immune response by acquiring host antigens thereby mimicking "self." 
Alt_ernative explanations include the release of soluble antigens with the 
formation of immune complexes which might block specific cellular or 
humoral effector mechanisms, alteration of lymphocyte responsiveness 
through interactions with macrophages, and the induction of T or B 
lymphocyte tolerance (18). In conclusion, the prolonged survival of M..,_ 
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pulmonis and the continued activation of the immune response may be 
responsible for all of the observed patholog ic phenomena in the 
respiratory disease . 
In addition to the chronic respiratory disease, !:L. pulmonis is 
capable of colonizing the urogenital tract of infected rats (28a). 
Naturally occurring disease in mice has not been reported but has been 
produced experimentally (26). The exact relationship of genital 
infections to respiratory mycoplasmosis is unknown as each has been 
detected in the absence of the other. Urogenital transmission of the 
organism may be via a hematogenous route, as !:L_ pulmonis has been shown 
to invade the blood system (18), or, since rats are copraphagic, by 
females harboring the organism in the upper respiratory passages 
transferring the infection to the vagina. Like the respiratory disease, 
the genital disease progresses slowly, subtle host-parasite interactions 
predispose to disease, there is an inconsistency in the lesions produced, 
and genetic factors influence severity (26). 
The most common lesions observed in the urogenital tract are 
perioophoritis and salpingitis ·(26), which are limited to approximately 
30-40% of infected females. Colonization of !:L_ pulmonis occurs on both 
squamous and nonsquamous epithelial cells. Epithelial changes include 
hyperplasia, squamous metaplasia and polyp formation. The fallopian 
tubes and ovaries may also become distended with the occurrence of 
neutrophilic exudate, hyperplasia and lymphoid infiltration (26). 
Usually, the uteri appear normal with organisms lining the entire 
epithelial surface, but occasionally an underdeveloped or partially 
resorbed fetus can be seen (26). No gross lesions have been observed in 
the vagina and cervix (18). 
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In contrast to the percentage of infected femal es, only 5% of males 
bred wi t h infected females contracted the infection . In males the 
organisms colonized the urethra, vas deference and epididymis , and were 
' found in association with ch ronic inflammation (24). 
The urogenital disease results in reduced fert ility in 50% of 
infected animals, which ranges from complete infertility to a 66% fetal 
loss after implantation (26 , 35). When pregnancy does occur, the organism 
is readily transmitted to offspring. Thus, t here is a continuous cycle 
of MRM in all breeding situations. 
Efforts to eliminate the disease have involved rigid selection of 
animals, couple d with administration of antibacterial drugs , or 
principles of cesarean derivation combined with strict isolation 
procedures (26,80). As previously mentioned, immunization of mice and 
rats has been demonstrated , but only in noninfected animals. In those 
cases, colonization by M.... pulmonis was not prevented. These approaches 
give only temporary e r adication of M.... pulmonis from rodent colonies. 
With the prevalence of MRM and the absence of effective eradication 
methods, t he usefulness of rodents for research purposes may be seriously 
questione d . This problem is enhanced by the variation in severity of tL_ 
pulmonis infection ( late ncy to lethality) . Lindsey et al. (48a) and 
others (22,47) have documented a large number of s pecific examples where 
MRM has complicated studies in the areas of respiratory disease , 
gerontological, nutritional, toxicological and behavior research. In 
addition , MRM affects many acute studies s uch as reproductive physiology 
and immunological studies . These complications have lead to MRM being 
declared as the number one problem in long term studies (80) . 
10 
Mycoplasmal Membrane Antigens and Activities 
In an effort to define mycoplasma pathogenesis and to produce 
effective methods of eradication, surface molecules from many mycoplasma 
species have been identified. These molecules may or may not be involved 
in virulence but, because they are immunogenic, they may have a potential 
role in pathogenesis. A few of these molecules have been characterized 
and at least one is involved in pathogenesis , the Pl attachment protein 
of M..._ pneumoniae. Other molecules have been suggested as potential 
virulence factors based upon in vivo or in vitro biological activities . 
This review will divide these molecules into three categories: membrane 
antigens, adherence factors, and membrane activities and potential 
toxins. 
Membrane Antigens 
Most mycoplasmal membrane antigens described in the literature were 
identified using antisera from naturally infected or experimentally 
immunized animals . Occasionally, the antisera against one mycoplasma 
species was used to identify cross-reactive surface proteins in another 
mycoplasma species. A summary of current information is presented in 
Table 1. The few proteins with characterized activities are noted. 
Adherence Factors 
In previous years, a large number of studies have been conducted on 
the identification and characterization of adherence factors and their 
receptors. Although not directly responsible for disease , adherence is 
necessary prior to colonization in the animal. Many adherence factors 
and proteins involved in hemagglutination have been postulated or 
identified. Razin (64) summarized previous information in 1985. Table 2 
is taken from that review, with the addition of current information 
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Table 1. Mycoplasma membrane antigens 
Mycoplasma 
species 
Straina 
t:L.. pneumoniae multiple 
Ml29 
Ml29 
Ml29 
t:L.. genitalium G-37 
t:L.. pulmonis 
G-37,M30 
5782 
Multiple 
63,47 
Negroni 
19612 
63 
auK - unknown. 
Molecularb 
weight 
170' 130' 90' 
45,35 
165-190 
78 
32 
110 
140 
95,87,79,72 
150-20, ladder 
86.5,83.5 
40,37,30 
bMolecular weight in kilodaltons. 
cc . R. - cross -reactive. 
Charac-c 
teristics 
Stable, 10 years (77) 
Pl protein involved in 
cytadherence, C.R. with 
140 kDa of t:L.. 
geni tali um ( 7) 
P2 protein, cytadherence 
(41) 
cytadherence(?) (37) 
C.R. with t:L.. pneumoniae 
(28b) 
MgPa, possibly involved in 
cytadherence, C.R . with Pl 
protein of t:L.. pneumoniae 
(7,40,57a) 
recognized by naturally-
infec ted antisera to t:L.. 
arthritidis (55a) 
V-1 an tigen comlex, single 
units of 30 kDa hydro-
phobic prote in fo rms 
multiple units, ac idic , 
var iable among strains 
(38,78,79) 
heat stable , 0.32 
e l ectrophoretic mobility 
(61) 
II 
Table 1 (continued) 
Mycoplasma 
species 
l:L. pulmonis 
Strain 
19612 
Negroni 
l:L_ arthr itidis 14124 PlO 
l:L. gallicep -
ticum 
l:L. synoviae 
l:L. bovoculi 
l:L. dispar 
l:L. arginini 
S6 C4 
UK 
PG-34 
UK 
UK 
UK 
UK 
12 
Molecular 
weight 
160,59 
125,28.5,27 
13-15 
64 
110 
165 
45-50 
94 
62 
89,85,74 
G230,23242 74 
G230,23243 70 
G230 
G230 
l:L. hominis PG-21 
44,17 
40,29,20 
102-38 
12 antigens 
Charac-
terist i cs 
heat stable , 0.32 
e l ectrophoretic mobility 
(61) 
" " 
Mitogen, secreted or 
excreted, basic, 
pI>9, affinity for high 
high molecular compounds 
(5) 
hemagglutination (14) 
C.R. to l:L. synoviae (63) 
C.R. to Pl protein of 
l:L. pneumoniae (28b) 
C. R. to l:L. gallicepticum 
(63) 
C.R . to l:L. dispar and 
l:L. arginini (70) 
C. R. to l:L. bovoculi (70) 
C. R. to M. bovoculi (70) 
heat stable (1) 
strain specific . (1) 
recognized by antisera 
to a common surf ace 
antigen common to most 
strains (1) 
102,87,78,72 recognized by 
infected human patients, 
102 present in 14 strains 
(21) 
Table 1 (continued) 
Mycoplasma 
species 
l:L.. hominis 
l:L.. hyorhinis 
l:L.. hyopneum-
iae 
Strain 
UK 
GDL 
GDL 
GDL 
GDL 
GDL 
GDL 
27719 
27719 
27719 
27719 
25934 
27719 
25934 
UK 
25934 
13 
Molecular 
we ight 
77 
23 
17 
18 
65,60,44 
51,38,46, 70 
120 
90 , 50 
30 
68 
26 
70,50,44 
90,68,50 
65 
64 
41 
Charac -
teristics 
prominent surf ace antigen 
(45) 
surface exposed , trypsin 
sensitive ( 69) 
trypsin insensitive ( 69 ) 
membrane bound portion 
after trypsin treatment of 
P23 (69 ) 
Lipid modified (15 ) 
surface exposed (13 ) 
surface exposed , trypsin 
sensitive (45) 
trypsin insensitive (45 ) 
surface exposed , t rypsin 
sensitive, related to P26 
(45) 
trypsin insensitive, 
related to P68 (45 ) 
lipid modified (80 ) 
lipid modified ( 80) 
antisera to protein 
recognized by multiple 
specie s of mycoplasmas (45 ) 
hemagglutination, trypsin 
insensitive , surface 
exposed ( 81 ) 
hydrophilic ( 45 ) 
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Table 2 . Adherence and hemagglutination factors 
Mycoplasma 
species 
M..... pneumon iae 
M..... gall i cepticum 
M..... genitalium 
M..... svnoviae 
M..... pulmonis 
M..... dispar 
M..... hyorhinis 
M..... hominis 
Receptor 
glycophorin, 
sialic acid 
sailogly-
coconjugates, 
glycophorin 
sialogly -
coconjugates 
sialogly-
coconjugates 
I: trypsin 
resistant 
II: trypsin 
sensitive 
ND, resistant 
to neuraminid-
ase, proteases, 
per iodate 
possibly Thy-I, 
other glyco-
proteins of 
lymphocytes 
proteins, 
resistent to 
neuraminidase, 
i nactivated by 
proteases and 
formalin 
aND - not determined. 
bkDa - kilodalton. 
CHA - hemagglutinin. 
dAtt. org . - Attachment organelle . 
Adhesinsa,b 
in kDa 
Pl (185) 
P2 (78) ? 
32 
ND 
MgPa (140) 
ND 
ND, trypsin 
resistant 
protein(s), 
trypsin sen-
sitive 
protein(s), 
sensitive to 
proteases 
ND 
proteins, 
sensitive to 
proteases and 
formalin 
HA inb,c 
kDa 
Pl (185) 
64 
Att.b 
org. 
+ 
+ 
+ 
15 
Table 2 (continued) 
Mycoplasma Receptor Adhesins HA in Att . 
species in kDa kDa org. 
!:L salivarum similar to M..,_ protein(s), 
hominis, more sensitive to 
readily inact- proteases, 
ivated by heat formalin 
and periodate 
!:L hyo:gneumoniae ND ND 64 , tryp-
sin sensi -
tive 
16 
(14,40,54,81). The hemagglutinating proteins and adherence factors have 
been shown in some cases to be identical , but in others, the relationship 
between hemagglutination and adherence acti vities has not been 
determined. 
The Pl protein, the major adherence protein of t:L_ pneumoniae, is the 
most well-studied mycoplasmal adherence molecule (33a). Pl protein is 
normally concentrated on the tip of the flask shaped organism, called the 
attachment tip, but is also found throughout the membrane . This allows 
t:L_ pneumoniae to have multiple binding sites with the host cell through 
sialoglycoproteins and glycolipids (41 ) and is probably responsible for 
its hemagglutinating activity . Viability is not required for this 
adherence. Other proteins beside Pl may be involved in adherence, 
including a 32 kDa protein ( 37 ,57b). In addition, monoclonal antibodies 
(Mab) and monospecific antisera to Pl have been used to identify cross-
reactive molecules in t:L_ genitalium and t:L_ gallicepticum (28b), the only 
other mycoplasma species containing tip structures. In t:L_ genitalium, a 
140 kDa protein demonstrated a high degree of cross-reactivity to Pl and 
this protein also appears to be localized on the tip structure (40,57a). 
It has not been conclusively shown whether this protein is responsible 
for adherence, although it is highly suggested. 
Attachment mechanisms of mycoplasma species which do not contain 
attachment tips (all species other than t:L_ pneumoniae, t:L_ gallicepticum , 
and t:L_ genitalium), have been studied less extensively . t:L_ pulmonis 
seems to adhere to host cells via a multifactorial process . The propos ed 
model of adherence involves an initial recognition event, the exposure of 
additional binding sites by the induction of membrane protein diffusion 
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on the eukaryotic cell surface, and the recognition and binding to these 
additional receptors by the mycoplasmas (54) . 
Membrane Activities and Potential Toxins 
Other than adhesions, mycoplasmas contain many membrane-bound 
activities involved in cell maintenance. These activities may have toxic 
properties under certain conditions. This area has been extensively 
reviewed by Gabridge (36). Tables III and IV are taken from this review 
with the addition of current data (2,17,51,54,60,70,75 ) . Most of these 
molecules have not been described in detail. The excep t ion is the M..,_ 
arthritidis mitogen (MAM). 
The 15 kDa heat-stable mitogen of M. arthritidis is the only 
identified mitogen in mycoplasmas, although several other species have 
membrane-associated mitogenic activities (Table III ) . M..,_ arthritidis is 
also unique in that the mitogen is either excreted or released from the 
membrane. M..,_ arthritidis mitogen (MAM) strongly activates H-2k bearing T 
lymphocytes and is dependent upon Ia-bearing, radioresistant adherent 
accessory cells bearing the alpha chain of the I-E encoded molecule of 
the murine major histocompatibility complex (MHC) (5,29 - 31 ) . The alpha 
chain of the I-E molecule appears to be the receptor for MAM ( 8) . 
Additionally, a non MHC-encoded gene is required for T lymphocytes to be 
responsive to MAM (29) . Processing of the mitogen by the accessory cells 
is not essential for activation. The MAM also stimulates both lymphocyte 
proliferation and the production of interferon. In summary, activation 
by MAM requires three different genes and the T cell receptor does not 
appear to be involved (8). 
A second activity that may be involved in pathogenesis is the 
membrane-bound hemolysin from M..,_ pulmonis. In all cases exc ept M..,_ 
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Table 3. Biological a ctivities of nonviable mycoplasma lysates (LY) and 
membrane ( MB ) preparations. 
Mycoplasma 
species 
M..._ mycoides 
M..._ fermentans 
M..,_ pneumoniae 
M..,_ arthritidis 
M..,_ synoviae 
M..,_ gallice:Qticum 
aPreparation . 
Prep.a 
MB 
LY 
MB 
LY 
MB 
MB 
LY 
LY 
MB 
LY 
Effect 
Casein cleavage 
Synovitis in calves 
Lethality in mice 
Cytotoxicity in thymocytes 
Mitogenic for mouse lymphocytes 
and human B and T lymphocytes 
Ciliostasis, necros is , decreased 
ATP content and decreased 
metabolism in tracheal explants, 
nonspecific attachment to 
tracheal cells , catalase i nhibition 
- -J - c ---· J ·•• - - ·· o ·----
guinea pig lymphocytes, mitogenic 
fo r mouse lymphocytes 
Immunosuppression in rabbits, 
suppression of inte rferon product-
ion in mice 
Inflammation in rabbit synovium, 
cytotoxicity, immunosuppression, 
inhibit mitosis, inhibit antibody 
production, suppression of 
i n terferon in mice, joint inflam -
mation in sensitized rabbits 
Mitogenic fo r mouse lymphocytes 
Binding to specific receptors 
on erythrocytes 
Mitogenic fo r mouse lymphocytes, 
binding to specific receptors 
on erythrocytes 
Table 3 (continued) 
Mycoplasma 
species 
!1..:.. neurolyticum 
!1..:.. hyopneumoniae 
!1..:.. hyorhinis 
!1..:.. pulmonis 
Prep . 
MB 
MB 
MB 
MB 
LY 
19 
Effect 
Mitogenic for rat B lymphocytes 
Cytotoxicity in fibroblasts 
Mitogenic 
Mitogenic for rat B and T lympho-
cytes, suppression of interferon 
production in mice, pneumoniae and 
tracheitis in rats, hemagglutin-
ation and hemolysis of 
erythrocytes , nuclease activity 
Inflammation in rabbi t synovium, 
suppression of interferon 
production in mice 
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Table 4. Potential toxins of Mycoplasmas 
Mycoplasma 
species 
M..,_ gallicepticum 
M..,_ orale 
M..,_ fermentans 
M..,_ mycoides 
M..,_ pnewnoniae 
M..,_ pulmonis 
Producta 
Putative 
Arginine 
deiminase 
Heat stable , 
trypsin sensitive 
lipid/prote in 
complex 
Galactan 
Diffusable toxin 
Phenol extract, 
lipoglycans 
Aggregates of 
membranes, sensi-
tive to sonication 
NaCl extract, 
>20 proteins plus 
carbohydrates 
Protein from 
membrane, protease 
sensitive , heat-
labile 
Protein from 
membrane , protease 
sensitive 
II II 
akDa - kilodalton . 
Biological Effect 
CNS inflammation, 
polyarteritis, toxicity in 
turkeys 
Lysis of L5178Y mouse 
lymphoma cells 
Lethal for mice 
Inflammation and edema in 
cattle 
Stimulates connective 
tissue proliferation 
pyrogenic, leukopenia 
Cytotoxicity and cilio -
stasis in hamster 
tracheal explants 
Ciliostatic; hemagglutin-
ating, proteoly tic; 
attachment inhibition 
Mitogenic for rat B and T 
lymphocytes 
Hemagglutinating 
Hemolytic activity 
Table 4 (continued) 
Mycoplasma 
species 
M.,_ bovis 
M.,_ neurolyticum 
M.,_ arthritidis 
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Product 
Ethanol extract 
polysaccharide, 
heat stable , not a 
protein or lipid, 
73 kDA 
Thermo labile 
protein, >200 
kDa 
Lipoglycans 
Proteins, heat-
labile, sensitive 
to oxidation, 
periodate 
13-15 kDa protein 
nondialyzable 
Biological Effect 
Eosinophilic mastitis in 
cattle 
Neurologic syndrome and 
death in mice 
Mitogenic for T and B 
lymphocytes, hemagglutin-
ating 
Mitogenic 
Mitogenic for rat lympho-
cytes 
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pulmonis, mycoplasma-associated hemolytic activities have been attributed 
to hydrogen peroxide production and are unrelated to pathogenesis or 
virulence, although cellular injury does occur (33b , 36). Intl..... pulmonis, 
two forms of hemolytic activity have been documented; hemolysis due to 
hydrogen peroxide and hemolysis caused by a membrane protein. Membrane-
associated hemolysis is dependent upon a helper factor (i .e. , bovine 
serum albumin), t emperature , and is more effective against trypsin-
treated red blood cells (52 ,53 ). The r e is evidence that this activity 
may play a role in the acquisition of cholesterol and phos pholipids from 
the membranes of red blood cells (50). The studies reported here show 
that the hemolysin is an 88.5 kDa prote in that remains bound to the 
membrane both in viable cells and membrane fragments . 
Microbial Hemolys in 
Bacterial hemolysins vary in size and mechanisms of action, with 
most being secreted. The extracellular hemolysins with known mechanisms 
of action can be divided into three categories: 1 . thiol-activated and 
pore - forming hemolysins; 2. phospholipases; and 3. surface active 
toxins. Several other extracellular hemolysins have been identified, but 
their mechanisms of a c tion are unknown . These are not included in this 
discussion . Finally , two membrane-bound hemolys ins have been identified 
and are discussed in the last section. 
Thiol-Activated and Pore-forming Hemolysins 
The thiol-activated or oxygen-labile hemolysins are produced by 
gram-positive bacteria . Best studied of these molecules are the 
streptolysin 0 (Streptococcus pyrogenes), theta toxin (Clostridium 
pe rfringes) , cerolysin (Bacillus cereus), pneumolysin ( Streptococcus 
pneumoniae) and tetanolysin (Clostridium tetani) (10). These hemolysins 
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share several properties. They are lethal and cardiotoxic, are 
inactivated under reducing conditions or by small amounts of cholesterol 
or other related sterols, and have similar pH and temperature optima for 
hemolytic activity (10,11). Most of them have a molecular weight between 
45-75 kDa (10). The initial step of lysis with these hemolysins is the 
binding to cholesterol, the membrane receptor. Lysis occurs either by 
the formation of hemolysin-cholesterol rings accompanied by a lipid phase 
transition, or by the formation of lysin pores (4). 
Besides the thiol-activated hemolysins, other extracellular products 
have been shown to cause pores in cell membranes. The best studied of 
these is the Staphylococcal alpha toxin (4). This toxin causes lysis by 
inserting itself into the membrane and forming hexamers, resulting in a 
pore. The mechanism of lysis has been termed "colloid-osmotic." 
Aerolysin from Aeromonas hydrophila has also been shown to function by 
this mechanism (10). 
Phospholipases 
Several different types of phospholipases have been identified in 
bacteria (10,SSb). Phospholipase A is usually cell bound, and is 
nonhemolytic (55b), as is phospholipase D (55b). Phospholipase C is the 
most common bacterial phospholipase and all are extracellular in nature. 
This enzyme is produced by both gram-positive and gram-negative species 
of bacteria, including Acinebacter, Pseudomonas, Staphylococcus and 
Clostridium (55b). Hemolysis is induced by cleavage of membrane 
phospholipids resulting in disruption of the normal membrane bilayer 
structure. The specificities of the bacterial phospholipases have been 
described in detail (4,6) . 
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Surface Active Toxins 
Surface active toxins are a group of small peptides capable of 
producing cell lysis either by forming aqueous channels which span the 
membrane or by increasing membrane permeability through the formation of 
other structures (4). These structural formations depend directly on the 
composition of the toxic molecules and its conformation in the membrane. 
Staphylococcal delta toxin is the best known bacterial toxin in this 
category (4,10). Most of the other toxins are found in snake venom and 
from insects. 
Membrane-bound Hemolysins 
Most bacterial hemolysins are excreted or secreted, as was noted 
above. In contrast to these are the membrane-bound hemolysins of 
Serratia species (46) and M..:.. pulmonis (52). A third hemolysin which 
remains associated with the membrane is streptolysin S (32). In the 
latter case, the 32 amino acid peptide can be released from the membrane 
by exposure to a carrier molecule, such as RNA. 
The hemolysins from both Serratia and M..:_ pulmonis remain bound and 
active in the cell membrane (46,52), but the mechanisms of action have 
not been determined. Hemolysis caused by Serratia requires viable 
organisms and the activity stimulates the release of histamine and the 
generation of leukotrienes. In contrast to Serratia, M..:_ pulmonis 
hemolysin does not require viable organisms since membrane fragments 
retain hemolytic activity (this study). The requirements for M..:_ pulmonis 
membrane-bound hemolysis also differ: the presence of serum or helper 
factors, trypsin-treated red blood cells, and 37°C (52) . The hemolysin 
is thought to be involved in cholesterol and phospholipid uptake from red 
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blood cells (50). Both Serratia hemolysins and the hemolysin from !:L.. 
pulmonis are thought to be involved in pathogenesis (46,52). 
The characteristics and requirements of the !:L.. pulmonis hemolysin 
indicate that the molecule is unique among bacterial h emo l ysins . It is 
unlikely to be a pore-forming h e molysin or a surface active toxin because 
it is not released from the me mbrane. An understanding of the mechanism 
involved may depend upon the identification and purification of the 
protein. The studies reported here identify the membrane protein 
involved in hemolysis and develop the reagents needed for future studies. 
In summary , !:L.. pulmonis is a surface parasite of rodents and is 
dependent upon nutrie nts derived from the host for survival. One of the 
major requirements is cholesterol, which maintains membrane fluidity in 
the absence of a cell wall. The role of the hemolysin in cholesterol 
uptake has been suggested (50), but additional studies need to be 
performed before the mechanism of action and the role of the hemolysin in 
pathogenesis can be determined . 
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SECTION I . PRODUCTION OF RAT ANTI-MYCOPI.ASMA MONOCLONAL ANTIBODIES 
FOLLOWING IN VITRO STIMULATION OF SPLEEN CELLS FROM NATURALLY 
INFECTED ANIMALS 
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ABSTRACT 
Spleen cells derived from rats naturally infected with Mycoplasma 
pulmonis were stimulated in vitro, and then fused with a mouse myeloma 
cell line. The resulting hybridoma supernatants were screened for 
mycoplasma-specific Mabs by ELISA and for HL-blocking activities. 
Fusions performed with in vitro stimulated SPCs yielded larger numbers of 
growth- positive wells and antibody-secreting cells than unstimulated SPCs 
from the same animals. Mabs capable of inhibiting !:L._ pulmonis HL 
activity were obtained, indicating that B cell priming during mucosal 
infections can provide SPCs suitable for hybridoma production . 
Key Words 
Rat monoclonal antibodies, naturally infected rats, in vitro 
immunization, mycoplasma 
Abbreviations 
BSA, bovine serum albumin; ELISA, enzyme-linked immunosorbent assay; 
FCS, fetal calf serum; HL, hemolysis; HS, horse serum; LPS , 
lipopolysaccharide; Mabs, monoclonal antibodies; MRBC , mouse red blood 
cells; PBS, phosphate buffered saline (pH 7.5); PBSG, PBS-0.5% glucose; 
PBST, PBS-0.05% Tween 20; SPCs, spleen cells. 
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INTRODUCTION 
Despite the continued efforts of many researchers, several factors 
hinder the identification of antigens contributing to the pathogenicity 
of microorganisms. For example, pathogens often express virulence 
determinants only in vivo or at greatly reduced levels in vitro. Also, 
epitopes may be lost during Western blotting and thus are not recognized 
by convalescent antisera . Finally, bacterial products may be 
immunosuppressive, preventing humoral immune responses against key 
virulence determinants. 
The identification of virulence-related proteins using Mabs derived 
from immunized animals has become routine. Recently, Takahashi et al. 
( 11) described an in vitro immunization technique using purified antigens 
to obtain specific Mabs . An adaption, discussed in this paper, takes 
advantage of the SPC priming which occurs during a natural infection. 
SPCs primed systemically by a natural infection were further stimulated 
in vitro by a modification of the method of Borrebaeck and Moller (2). 
In vitro immunization has several advantages; the immunization period is 
shortened (3 days), smaller quantities of antigen are required (0. 1-10 
ug), Mabs can be produced against antigens or epitopes that are weakly 
immunogenic (11), and the primed B cells may be removed from a 
potentially inhibiting environment. Additionally, our modification does 
not require the immunization of infected animals, which may result in 
death or potentiation of adverse reactions such as immunosuppression ( 1 ) 
or tolerance. 
Mycoplasma pulmonis colonizes the respiratory a~d genital tracts of 
rodents, inducing local and systemic immune responses (3). Minion and 
Goguen (7) identified a membrane-bound hemolytic activity which may have 
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a role in cholesterol acquisition (6) and may be virulence-related. In 
the studies reported here, hemolysin blocking antibodies were found to be 
present in sera from infected animals, but absent in hyperimmune 
antisera. In order to identify this protein, a series of hybridoma 
fusions were performed using SPCs from naturally infected rats. The SPCs 
were either used directly or stimulated in vitro with mycoplasma antigen 
and adjuvant. Fusions incorporating in vitro treated SPCs demonstrated 
higher percentages of growth-positive wells and antibody-secreting 
hybridomas than fusions u s ing untreated SPCs. The resulting Mabs were 
screened for their ability to block hemolytic activity, and are currently 
being used to identify the hemolysin. 
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MATERIALS AND METHODS 
Mycoplasma Cultures 
tl..._ pulmonis strains UAB6Sl0 (9) and ISM3001 were cultured in PPLO 
broth or on PPLO agar media supplemented with 10% gamma globulin-free 
horse serum (Gibco Laboratories, Grand Island, NY) . Overnight mycoplasma 
cultures were harvested in mid-log phase (pH 7.2-7.4). Organisms were 
pelleted, washed, resuspended in PBSG, and protein concentrations of cell 
suspensions determined using the Bio-Rad protein assay (Bio-Rad 
Laboratories, Richmond, Cal.) with BSA as the standard according to 
manufacturer's directions. 
Animals 
Sprague-Dawley rats (SASCO, Inc. , Omaha, Neb.) and BALB/cByJ mice 
(Jackson Laboratories, Bar Harbor, Ma.) were housed at the Laboratory 
Animal Resource Division of the College of Veterinary Medicine, Iowa 
State University. 
Antigen Preparation 
Antigens used for mouse immunizations and for the rat in vitro 
stimulation assays consisted of UAB6Sl0 whole cells suspended in H2o and 
frozen at -70°c. BALB/cByJ mice were intraperitoneally immunized with SO 
ug antigen in incomplete Freund's adjuvant intraperitoneally and boosted 
with an identical dose 14 days later. Rabbits were immunized with whole 
cell lysates or purified membranes as previous ly described (9). 
Experimental Mouse Infections 
BALB/cByJ mice were infected with SO ul of mid-log culture of 
UAB6Sl0 intranasally. One week post infection , blood was obtained by 
retino-orbital puncture , and sera were tested by ELISA. Two weeks later, 
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animals were anesthetized with methoxyflurane (Pitman-Moore Inc., 
Washington Crossing, NJ) and blood obtained by cardiac puncture. 
Monoclonal Antibody Production 
Rat SPCs and mouse myeloma P3X63-Ag8.653 cells were mixed together 
at a 5:1 ratio, fused with polyethylene glycol 1500 (Boehringer Mannheim, 
West Germany) and plated at a cell density of 5 x 105 cells/well in 24 
well plates (Corning 25820). Selective medium consisted of RPMI 1640 
medium (Gibco Laboratories, Grand Island, N.Y.) containing 15% 
heat-inactivated FCS, 10% conditioned medium, 1.2% MEM Non Essential 
Amino Acids (Gibco), 0.3 g/L L-glutamine, and hypoxanthine-aminopterin 
-thymidine media supplement (Sigma Chemical Co. , St. Louis, Mo .). 
Conditioned medium was prepared by suspending BALB/cByJ mouse SPCs (1 x 
106 cells/ml) in RPMI 1640 medium containing 10% FCS and L-glutamine for 
three days . The resulting supernate was collected, filter-sterilized, 
and stored at -20°c until use. Hybridomas were screened for 
mycoplasma- specific antibody production by ELISA (see below). Subcloning 
was performed using the Autocloner accessory on an EPICS VII fluorescence 
activated cell sorter ( EPICS model 752). All hybridomas and subclones 
were frozen in medium containing 15% dimethylsulfoxide in liquid nitrogen 
and supernates from confluent cell cultures were stored at -70°c. 
In Vitro Stimulation 
Rat SPCs were obtained from naturally-infected animals and suspended 
at a concentration of 2 x 106 cells/ml in RPMI 1640 supplemented with 15% 
heat-inactivated FCS, 10% conditioned medium, 1.2% MEM Non Essential 
Amino Acids (Gibco), 0.3 g/L L-glutamine and 5 x 10-5 M 2-mercaptoethanol 
(tissue culture grade). Cells were plated into 24 well plates (Corning 
25820, 0.5 ml/well), and the following were added to each well: 10 ug 
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indomethicine, 10 ug of sterile UAB6510 whole cell antigen and 5 ug E....:_ 
coli K235 LPS. The plates were rocked for three days at 37°C in an 
atmosphere of 83% N2 - 7% o2 - 10% C02, and fed daily with the above 
medium. After incubation, the cells were collected and fused with the 
mouse myeloma line as described above. 
ELISA 
ELISA plates were prepared by coating 96 well serocluster "U" vinyl 
plates (Costar 2797) with 100 ul of mycoplasma antigen (5 ug/ ml) 
suspended in coating buffer (0.1 M sodium carbonate - 0.02% sodium azide , 
pH 9 . 6) for 5 h at 37°C or overnight at room temperature. Plates were 
washed three times with wash solution (0.9% NaCl - 0.05% Tween 20 ), 
incubating 5 minutes at room temperature between washes, and stored at 
-70°c until use. 
Thawed ELISA plates were washed twice with wash solution, and 
blocked with PBS - 0.5% BSA for 30 minutes at room temperature. The 
plates were then washed three times with wash solution, and undiluted 
hybridoma supernate (100 ul/ well) or polyclonal sera (100 ul/ ml , 1:100 
dilution in PBST) was added to the wells , and the plate incubated 
overnight at room temperature. The plates were again washed three times 
prior to the addition of rabbit anti-rat IgG (Kirkegaard and Perry 
Laboratories, Inc., Gaithersburg, Md) or goat anti-mouse IgG (BioRad 
Laboratories, Richmond, Ca) horseradish peroxidase conjugate (100 
ul/well, 1:2,000 dilution in PBST). The plates were incubated for 1 hat 
37°c, washed four times, and 3,3' ,5,5'-tetramethylbenzidine (Kirkegaard 
and Perry Laboratories, Inc.) was used as substrate according to 
manufacturer's directions . ELISA plates were read on a Bio-Tek Automated 
Microplate Reader (Model EL310). 
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Hemolysis Assay 
The standard HL assay mixture consisted of assay medium (RPMI 1640, 
20 mM HEPES, 1% BSA, pH. 7.S), 0.S% trypsin-treated MRBCs (final 
concentration) prepared according to Minion and Goguen (7), and freshly 
prepared UAB6Sl0 in a total volume of 1 ml . This mixture was rocked 
slowly for l.S hat 37°C and lysis determined by measuring optical 
density at 630 nm. The minimal amount of mycoplasma protein needed to 
lyse the MRBCs was determined for each mycoplasma culture to adjust for 
day to day variation. The HL inhibition assay was performed by 
statically treating this concentration of mycoplasmas with antibody for 
h 37°C prior to the addition of MRBCs. Sera from immunized or infected 
animals were diluted 1:2S in assay media. Hybridoma supernatants were 
used undiluted (300 ul). After incubation with antibodies, MRBCs were 
added and the total volume adjusted to 1 ml with assay medium. Optical 
density readings were taken at times 0 and l.S h. Controls consisted of 
MRBCs alone (negative control), mycoplasmas and MRBCs in assay media 
(posit ive control), and mycoplasmas and MRBCs with a known HL blocking 
antisera (HL blocking control) . Percent inhibition was defined as 1 -
(To - Tl.Sh experimental] /( To - Tl.Sh positive control] X 100. 
1 
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RESULTS 
A Sprague-Dawley rat colony presenting typical mycoplasma disease 
symptoms was screened for mycoplasma infection by standard culture 
techniques (4). Mycoplasma isolates from these animals were filter-
cloned (12) and positively identified as !:!..:.. pulmonis by using a 
fluorescent antibody test (5). One of these isolates was designated 
ISM3001. Animals from this colony displaying typical mycoplasmal disease 
symptoms were used in the hybridoma fusion experiments. All mice 
experimentally infected with UAB6510 demonstrated clinical signs of the 
disease and had high serum antibody titers as determined by ELISA. 
Hybridoma Fusions 
The results of fusions 1 and 2 , which were performed using SPCs 
taken directly from mycoplasma-infected animals, are shown in Table 1. 
Fusion efficiencies were low (8-25%) and most wells did not contain 
mycoplasma-specific antibodies as determined by ELISA. To test whether 
in vivo primed SPCs could be expanded in vitro and used efficiently in 
hybridoma fusions, cells from the same source as cells used in fusions 1 
and 2 were cultured in vitro in the presence of antigen and LPS for three 
days prior to fusion (Table 1, fusions 3 and 4). In vitro stimulation 
increased both the percentage of growth-positive and antigen-specific 
(ELISA positive) wells. 
Hemolysis Inhibition Assay 
Figure 1 shows the results of the HL blocking assay. Hyperimmune 
rabbit and mouse sera failed to block!:!..:.. pulmonis-mediated HL activity, 
but both experimentally infected mouse and naturally infected rat sera 
were capable of blocking HL. Hybridoma supernatants with more than SO i. 
inhibitory activity were considered positive. 
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Table 1 . Effect of in vitro stimulation on production of M...:.. 
pulmonis-specific r at hybridomas 
Fusion 
Numb era 
1 
2 
3 
4 
Percent Growth 
Positiveb 
8 
8 
88 
74 
Percent ELISA 
Positive 
2 
0 
69 
16 
aFusions 1 and 2 used unstimulated naturally infected rat SPCs; 
fusions 3 and 4 used in vitro stimulated, natural l y infected rat SPCs 
from the same animals as fusions 1 and 2, respectively. 
boata are presented as the percentage of growth positive or ELISA 
positive wells from the total number of wells plated for each fusion . 
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Hemolysin blocking activities of r abbit, rat, and mouse 
antisera , and rat Mabs . (.A) hyperimmune rabbit a n tisera; 
(6.) hyperimmune mouse antisera; (• ) experimentally infected 
mouse antisera ; (O) naturally infected rat sera ; (0 ) rat 
Mabs; (e ) mouse Mabs. Data are presented as percent 
inhibition as defined in the text. 
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DISCUSSION 
Previous studies on the membrane activities of !:!.,_ pulmonis 
demonstrated the presence of a trypsin-sensitive hemolysin (7 ) which may 
be involved in cholesterol uptake from adjacent eukaryotic membrane 
surfaces (6) . I dentification of the HL protein was hindered by the lack 
of hyperimmune antisera capable of blocking its activity (Figure 1 ) . The 
results with sera from naturally or experimentally infected animals, 
however, showed that antibodies could block hemolytic function . 
Rats used in these experiments were from a Sprague-Dawley colony 
with a history of chronic respiratory disease . The !:!.,_ pulmonis strain 
detected in this colony by culture and immunofluorescence, ISM3001 , was 
antigenically similar to our laboratory strain UAB6510 by Western blot 
analysis (8) . Importantly, the sera from these animals blocked the HL 
activity of strain UAB6510 (Figure 1) . 
Initial fusion experiments with untreated SPCs from naturally 
infected rats resulted in few ELISA positive, mycoplasma specific 
hybridoma supernatants (Table 1). This indicated that some antigen 
specific B cells were present in the rat SPC preparations although their 
numbers were low. Since only a few primed B cells give rise to 
successful hybridomas , it was necessary to increase the numbers of primed 
antigen specific B cells, and consequently increase the likelihood of 
obtaining hemolysin specific Mabs. This was accomplished by exposing the 
cells to mycoplasma antigen and an adjuvant , ~coli LPS , in vitro for 
three days (Fusions 3 and 4) , resulting in an increase in both the number 
of growth- positive wells and antigen-specific hybridomas (Table 1) . 
Mabs which block hemolytic activity have been identified (Figure 1) 
supporting the hypothesis that in vitro stimulation can be used 
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effectively to produce Mabs to antigens recognized primarily during 
infectious processes . This is further substantiated by the observation 
that approximately 50% of the Mabs obtained were of the IgG2b isotype 
(data not given), and thus primed B cells were present prior to the three 
day in vitro stimulation. 
The ability to produce Mabs from SPCs obtained from naturally 
infected animals offers a practical solution to many problems in 
hybridoma research. A natural host may not be required as long as 
colonization of the host and stimulation of its humoral defense occurs. 
With the widespread use of rodents for the study of pathogenic mechanisms 
and the use of alternate fusion partners (i.e., rabbit - mouse or swine -
mouse, etc ., 10), the development of Mabs to virulence determinants not 
generally recognized by rodents may become possible . Further enhancement 
of this technique through the use of in vivo grown organisms to aid in 
the screening of Mab libraries may lead to the discovery of previously 
unrecognized virulence-related antigens. 
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ABSTRACT 
Mycoplasma pulmonis lysis of trypsin-treated red blood cells in 
suspension requires contact between the mycoplasma and the red blood 
cell, and is mediated by a trypsin-sensitive membrane protein. In order 
to identify this protein, acute and hyperimmune sera were screened in a 
hemolytic blocking assay. Sera produced by infected rodents, but not by 
animals immunized with broth grown organisms were able to block hemolytic 
activity. Monoclonal antibodies (Mabs ) were also produced to M....:_ pulmonis 
membrane proteins using spleen cells from naturally infected rats and 
mice . Several Mabs which demonstrated anti-hemolysin activity were used 
in radioimmune precipitation assays to identify the hemolysin, a 88.5 
kilodalton protein. These Mabs were shown to be specific for the 
hemolysin by the following criteria: they reacted strongly in an enzyme-
linked immunosorbent assay using intact whole cells, purified membranes, 
or tryptic peptides released from the rnycoplasma surface as antigens; 
these tryptic peptides could interfere with the anti-hemolytic activity 
of the Mabs ; Fab fragments of these Mabs we re 50-70% effective in 
blocking hemolysis; and intact Mabs were unable to block attachment of 
the organism to red blood cells . 
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INTRODUCTION 
Hemolysins ( HLs ) which are diverse in size, structure and mechanism 
of action, h ave been shown to be important virulence determinants in a 
variety of bacterial species (2,16 ,17, 26). Several demonstrate 
phospholipase activity (1,3,4), and at least one is membrane bound (17). 
Many mycoplasmas are important animal and plant pathogens, and have 
demonstrated a nonvirulence-related agar plate hemolytic activity (5, 12, 
14) resulting from production of hydrogen peroxide ( 11). A second 
hemolytic mechanism involving a trypsin sensitive membrane protein has 
been described for Mycoplasma pulmonis (21,22). This mechanism differs 
from agar plate hemolysis in that only trypsin-treated red blood cells 
(RBCs) are lysed, a helper or carrier molecule is required, and l ysis 
occurs rapidly in suspension presumably when the !:L_ pulmonis membrane 
contacts or attaches to the RBC surface (22). The role of this activity 
in virulence has not been established, but it is though t to be involved 
in the acquisition of membrane precursors from eukar yotic membranes (21 ) . 
Understanding the mechanism of membrane-associated hemolys is is 
complicated by the fact that !:L_ pulmonis has other mul tifactorial 
membrane properties. For instance, adherence has been shown"to involve 
at least two different mechanisms, a trypsin resistant form ( Ty pe I) and 
a protein mediated form (Type II ) (23). Differentiation between the 
hemolysin and the Type II adhesion is difficult b ecause both act i vities 
are observed using trypsin-treated RBCs and both are protease sensitive. 
Therefore, both activities may be part of the same multifunctional 
protein molecule (22). Another membrane activity, hemagglutination, may 
also be associated with the Type II adhesion (22). 
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The goal of this study was to identify the protein involved in 
hemolysis and determine its relationship to Type II adherence. To 
accomp l ish this goal, a monoclonal antibody (Mab) library to !:L_ pulmonis 
prote ins was produced a n d screened for anti-hemolytic activity. Several 
Mabs capable of blocking HL activity were obtained and three were chosen 
for further study. These Mabs recognized an 88.5 kilodalton (kDa ) 
membrane protein by radioimmune precipitation (RIP) assays, and failed to 
block attachment to trypsin-treated RBCs in adherence assays, thereby 
differ entiating the membrane hemolysin and Type II adherence properties. 
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MATERIALS AND METHODS 
Culture Conditions and Antigen Preparations 
!:L_ pulmonis strains UAB6510 (24) and ISM3001 were cultured in PPLO 
broth without crystal violet (Difeo Laboratories, Detroit, Mich.) 
supplemented with 10% serum, 0.5% glucose, 2.5% fresh yeast extract (Flow 
Laboratories , Inc., McLean, Va.), and 25 ug of Cefobid (Pfizer , Inc ., New 
York, N.Y.) per ml . Agar plates contained 1% Noble agar (Difeo). Serum 
supplements consisted of gamma globulin-free horse serum (GIBCO 
Laboratories, Grand Island, N.Y.) or rabbit serum (GIBCO). Cultures were 
incubated at 37°c, and harvested in mid log phase (pH 7.3). Mycoplasmas 
were cultured from rat lungs and uterine horns using standard techniques 
(8), filter-cloned (27), and identified as !:L_ pulmonis by plate 
epiimmunofluorescence ( 15a). 
Mycoplasmal Antigens 
Mycoplasma whole cell immunizing antigen consisted of organisms 
grown in PPLO medium supplemented with 10% serum. These organisms were 
pelleted by centrifugation (10,000 x g, 20 min) , washed three times with 
10 mM Na2HP04 - 140 mM NaCl , pH 7 .5 (PBS), and lyophilized or resuspended 
in sterile PBS (approximately 1 mg protein per ml) and stored at -70°c 
until use. Membranes were prepared from washed organisms by osmotic 
lysis as previously described (23). 
Trypsin-released peptide (TRP) antigen was prepared by resuspending 
washed, whole organisms from 2 Lo~ broth in 10 ml of PBS - 0.5% glucose 
(PBSG), and treating with 1 ml of immobilized trypsin (Cooper Biomedical, 
Inc., Malvern , Pa.) overnight at 37°C with gentle agitation. The 
immobilized trypsin and the organisms were removed by centrifugation 
(10,000 x g, 10 min), and the resulting supernate concentrated in a 
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SpeedVac (Savant Instruments, Inc . , Farmingdale, N. Y. ) and filter-
sterilized. Protein concentrations were determined using the dye binding 
protein assay (Bio-Rad Laboratories , Richmond, Calif . ) and bovine serum 
albumin as the standard. 
Mycoplasma enzyme-linked immunosorbent assay (ELISA) lysed antigen 
was prepared as above except that cells were washed and resuspended in 
water at 2 - 3 mg protein per ml prior to dilution in carbonate lysis 
buffer. Trypsin-treated ELISA antigen was prepared by treating whole 
cells resuspended in PBSG with trypsin ( 100 ug trypsin per mg M...... pulmonis 
protein) for 1 h at 37°C, and washing the cells three times with PBSG. 
These antigens were stored at -70°c prior to use. 
Immunoreagents 
New Zealand White rabbits (Small Stock Industries, Pearidge , Ark.), 
Sprague-Dawley rats (SASCO Inc., Omaha, Neb.) and BALB/cByJ mice (Jackson 
Laboratories, Bar Harbor, Maine) were housed at the Laboratory Animal 
Resources Division of the College of Veterinary Medicine, Iowa State 
University. Rabbits were immunized with rabbit or horse serum grown 
antigen suspended in PBS at 0.1 mg protein per ml as previously described 
(6). Experimentally infected mouse sera was obtained by inoculating six 
BALB/cByJ mice intranasally with 1 X 108 colony forming units of UAB6510 
in 0.05 ml of mycoplasma broth supplemented with horse serum. The mice 
were sacrificed after two weeks and sera pooled. Sera were also obtained 
from M...... pulmonis naturally infected Sprague-Dawley rats. 
Hybridoma Production 
BALB/cByJ mice were immunized with 100 ug of mycoplasma whole cell 
antigen suspended in PBSG or 10 ug of TRP antigen . Primary injections 
were given intraperitoneally and secondary boosters given 14 days later 
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intravenously. Blood was obtained on days 1, 14, and 17 by retino-
orbital puncture. Spleen cells were also obtained from untreated rats 
naturally infected with M..:.. pulmonis . 
Myeloma fusions were performed with rat or mouse spleen cells (SPCs) 
and mouse myeloma P3X63-Ag8.653 cells (ATCC CRL 1580) using standard 
techniques. Hybridomas were screened for mycoplasma-specific antibody 
production by ELISA. Subcloning was performed using the Autocloner 
accessory on an EPICS VII fluorescence activated cell sorter (model 752 ). 
Antibody isotypes were determined using the Mouse Subtyping Kit ( BioRad), 
or the Rat Isotyping Kit (Serotek, England) according to manufacturers 
directions . 
In Vitro Stimulation of Rat Spleen Cells 
Rat SPCs obtained from naturally infected animals were suspended at 
2 x 106 cells per ml in RPMI 1640 supplemented with 15% heat-inactivated 
FCS, 10% conditioned medium, 1.2% MEM Non-essential amino acids (GIBCO), 
0 . 3 g L-glutamine per liter and 5 x 10-5 M 2-mercaptoethanol (tissue 
culture grade) . Cells were cultured into 24 well tissue culture plates 
(Corning 25820 , 0.5 ml per well), with the following additions per well : 
10 ug indomethicine, 10 ug of UAB6510 whole cell antigen and 5 ug .L_ coli 
K235 LPS . The plates were rocked for three days at 37°c in an atmosphere 
of 83% N2, - 7% 02 - 10% C02, and the wells fed daily with the above 
medium . After incubation, the cells were collected and fused with the 
mouse myeloma line as described above. 
Monoclonal Antibody Concentration and Fab Fragments 
Hybridomas were adapted to grow in HL-1 medium (Ventex, Fisher 
Scientific Co . , St . Louis, Mo.) with a 0 . 5% f e tal calf serum 
concentration, and culture supernates concentrated using an Amicon 
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concentrator with 15,000 molecular weight cutoff filters (Arnicon 
Division, W. R. Grace & Co., Danvers, Maine). The antibodies were 
precipitated with 36% sodium sulfate , washed twice with 18% sodium 
sulfate by centrifugation , and dialyzed against PBS overnight at 4°C. 
Antibodies were again concentrated using the Arnicon concentrator, protein 
concentration determined, and their activity assessed by ELISA prior to 
use. Fab fragments were produced using immobilized papain (Pierce 
Chemical Co., Rockford, Ill .) according to manufacturer's suggestions. 
The extent of digestion was determined by analyzing samples of the 
digests by sodium dodecyl sulfate polyacrylamide gel electrophoresis 
( SOS-PAGE) (23). 
ELISA 
The ELISA was performed with carbonate buffer-lysed antigen as 
described (7). Plates for the whole cell ELISA were prepared by treating 
96 well serocluster "U" vinyl plates (Costar, Cambridge, Mass.) with PBS 
- 0.1% glutaraldehyde for 4 hat room temperature or overnight at 4°c. 
Plates were then washed three times with PBS, coated with intact 
organisms suspended in PBS - 0 . 1% glutaraldehyde (5 ug per ml, 100 ul per 
well ) for 4 h, and the wells blocked for 1 . 5 h at room temperature with 
PBS - 1% BSA . Undiluted hybridoma supernates or antisera diluted in 
PBS - 0 . 1% BSA (1/100) was incubated in the wells overnight at 4°c. 
Plates were again washed three times with PBS - 0.1% BSA prior to the 
addition of horseradish peroxidase labeled goat anti-mouse IgG (H+L) 
(Bio-Rad), 100 ul per well , 1:3000 dilution in PBS - 0.1% BSA. The 
plates were incubated for 1 hat 37°C, washed three times with PBS , and 
3,3' ,5,5'-tetramethylbenzidine (Kirkegaard and Perry Laboratories, Inc ., 
Gaithersburg, Md .) was used as substrate according to manufacturers 
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directions. ELISA plates were read on a automated microplate reader 
(BioTek, Model EL310, Winooski , Vt.) . 
RBC Preparation and Hemolytic Assays 
Mouse RBCs (MRBCs) for the hemolytic assay were prepared essentially 
as described (23). Blood was collected in Alsevers anticoagulent, washed 
in PBSG three times, treated with trypsin for 30 min (1 mg per ml, 8% 
suspension) with gentle agitation , washed in PBSG three more times, and 
resuspended in the same buffer. The standard HL assay mixture consisted 
of assay medium (RPMI 1640 - 20 mM HEPES - 1% BSA , pH. 7.5), 0.5% 
trypsin-treated MR.BCs (final concentration), and fre shl y prepared UAB6510 
(approximately 10 - 15 ug protein) in a total volume of 1 ml . The 
mixture was rocked slowly for 1.5 h at 37°C and lysis determined by 
measuring optical density (630 run) at 0, 45 and 90 min. The minimal 
amount of mycoplasma protein needed to completely l yse the MR.Bes was 
determined for each mycoplasma culture to adjust for variation in 
hemolysin concentration. The HL inhibition assay was performed by 
treating this concentration of mycoplasmas with antibody (sera diluted 
1 :25 in assay medium or 300 ul of undiluted hybridoma supernate) for 1 h 
statically at 37°C prior to the addition of MRBCs to bring to final 
volume . Controls consisted of MR.Bes alone (negative control), 
mycoplasmas and MR.Bes in assay medium (positive control), and mycoplasmas 
and MR.Bes with a known HL blocking antisera (HL blocking control). In 
some experiments 20 - 30 ug TRPs were added along with the Mabs. In 
these experiments , mycoplasmas with TRPs, and TRPs with MRBCs only served 
as additional controls. After incubation with antibodies, MR.Bes were 
added and the total volume adjusted to 1 ml with assay medium. Percent 
inhibition was defined as: ( DC - DE )/DC x 100 where DC - optical density 
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(0.D.) at 0 min - O.D. at 90 min for the positive control, and DE - O.D. 
at 0 min - O.D. at 90 min for the experimental . 
Radioimmune Precipitation Assay 
Intrinsically radiolabeled organisms were prepared as described (22) 
using 35s-labeled amino acids (Trans 35s, ICN Biomedicals, Inc., Costa 
Mesa, Calif.). The RIP assay was performed as described (23) except that 
1 - 3 ug protein of purified Mab were used in some assay mixtures. Rat 
and mouse antibodies were precipitated using biotinylated rabbit anti-
mouse IgG + lgM (H+L) (Sigma) or rabbit anti -rat lg (IgGl , IgG2a• IgG2b• 
lgG2c, lgM, lgA, Fe and Fab) (Nordic Immunological Laboratories, 
Capistr ano Beach, Calif. ) and Streptavidin agarose (Sigma). Biotinylated 
antibodies were prepared fresh using photoactivatible biotin (CLONTEK 
Laboratories, Inc ., Palo Alto, Calif .) according to the manufacturers 
directions. Rabbit antibodies were precipitated using Sepharose-Protein 
A (Sigma) as described (23). 
Adherence Assay 
The mycoplasma - RBC adherence assay was performed essentially as 
described (24) using both untreated and trypsin-treated human RBCs. The 
effect of antisera, hyperimmune rabbit, naturally infected rat, and anti-
hemolysin Mabs was examined by incubating the organisms in a 1 : 10 
dilution of antisera or undiluted hybridoma supernates for 1 - 2 h at 
37°C. MRBCs were then added directly to the mycoplasma - antibody 
mixture. Controls consisted of untreated organisms, and organisms 
treated with antibodies without RBCs . Effect on adherence was determined 
by taking the difference in the 0 and 60 min time points for each 
treatment and subtracting the treated organisms less RBC control for each 
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treatment. This accounted for any aggregation of the organisms as a 
result of antibody treatment. 
Electrophoresis 
Polyacrylamide gel electrophoresis was performed by a modification 
of the method of Laemml i (19) using an upper tray buffer of 3 g Tris per 
L, 14.5 g glycine per L, and 1 g SOS per L ( pH 8.5), and a lower tray 
buffer diluted 1:1 with water. Proteins were separated using a 3% 
acrylamide stacking and a 10% acrylamide resolving layer. Molecular 
weight standards consisted of high molecular weight standards (Bethesda 
Research Laboratories, Gaithersburg, Md. ) and rainbow standards (Amersham 
Corp., Arlington Heights , Ill.). Proteins were visualized by Coomassie 
blue or silver staining (20) for determination of apparent molecular 
weights and by autoradiography for identification of radiolabeled 
proteins. Gels with 35s-labeled proteins were impregnated with 1 M 
sodium salicylate for 30 min prior to drying to enhance the radiographic 
signals . 
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RESULTS 
Rats and Mice 
Sera from naturally infected rats were obtained from a colony with 
severe mycoplasma disease. Sera antibody titers to !:L.. pulmonis UAB6510 
were high (>2.0 optical density units above background controls), lungs 
had extensive lymphocytic involvement (9), and mycoplasmas were cultured 
from lung tissues and identified as !:L.. pulmonis by colony epifluorescence 
(15) . Mice had low positive mycoplasma antibody titers by ELISA which is 
typical of low level, clinically silent mycoplasma disease (10) . After 
immunization, their antibody titers to UAB6510 were equal to or greate r 
than the titers from the infected rats. 
Hybridoma Fusions 
Spleen cells from untreated naturally infected rats were stimulated 
in vitro with mycoplasma antigen and ~ coli lipopolysaccharide resulting 
in an 8 - 10 fold increase in fusion efficiency as compared to 
nonstimulated SPCs (data not given). Both the percentage of growth -
positive wells and antigen-specific (ELISA positive) wells demonstrated 
similar increases (data not given). Additional fusions were performed 
using mouse SPCs from immunized animals as noted above. Mouse SPCs were 
not stimulated in vitro prior to fusion . 
Monoclonal Antibodies 
Mouse and rat hybridomas were screened using different ELISA 
antigens . Mouse Mabs which demonstrated high ELISA values , reactivity in 
the whole cell ELISA, or decreased binding to trypsin-treated antigen 
were studied further. All of the rat hybridorna supernates were included 
in these studies. Antibody isotypes included mouse IgA , IgM, and all IgG 
subtypes, and rat IgM and IgG2b (Table 1 ) . 
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Hemolytic Acti v ity of tL._ pulmonis 
A typical hemolys i s curve is shown in Fig. 1 . Optical density 
readings were taken at 0, 45 and 90 min as was suggested by previous 
studies which indicated complete lysis of MR.Bes by tL._ pulmonis in 90 min 
(22). Naturally infected rat sera and the two Mabs shown prevented lysis 
of MRBCs ( Fig . 1 ). Mouse and rabbit hyperimmune antisera , however, 
failed to block hemolysis as indicated by the similarity of the lysis 
curve to the positive control. Rabbit antisera produced against whole 
mycoplas ma cells, purified membranes, and cytoplasmic proteins were 
tested and all failed to block hemolysis (data not given). The 
hyperimmune sera and the naturally infected rat sera reacted strongly in 
the ELISA and on Western blots (data not given) indicating their 
recognition of multiple !:L_ pulmonis antigens, some of which were external 
membrane proteins (data no t given). 
Effects of Monoclonal Antibodies on HL Activity 
Test samples were compar ed with three controls: mycoplasmas plus 
MR.Bes, MR.Bes only, and mycoplasmas treated with naturally infected rat 
sera plus MR.Bes ( HL-blocking control ) . Onl y those which demons trated 75% 
or greater inhibition were considered for further study. Three 
hybridomas ( l e5B9, 1B3Gl, and 1D4Gl2) demonstrating high inhibitory 
activity were partially purified. These Mabs recognized a tryptic 
peptide released from the tL._ pulmonis membrane as evidenced by the 
abili t y of TRP preparations to block t he ir an ti-HL activity and by a 
positive ELISA reaction to these pep t ides (Table 1). Fab fragments from 
these Mabs r etained greater than 50% of the hemolysis blocking activity . 
Several other Mabs which were positive in the whole cell ELISA failed to 
block anti-HL acti vity (2e3F2, 7D2Bl0, 12e3Bl, 12D2All, and 11C2A5) 
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demonstrating that anti-HL activity by Mabs was due to antibody binding 
to a specific antigen and not to steric hindrance , or other nonspecific 
effects. 
Effect of Antisera and Mabs on Adherence to Human Red Blood Cells 
To accommodate the inclusion of an antibody incubation step in the 
adherence assay, control tubes containing only organisms and antibodies 
were monitored in each treatment to eliminate any effect antibody-
mediated agglutination may have had on the assay. Hyperimmune rabbit and 
naturally infected rat sera, and the monoclonal antibodies did not 
increase the background counts demonstrating that the counts at the 60 
min interval represented actual binding of organisms and not aggregates 
of mycoplasmas. When compared to mycoplasmas alone, anti-hemolysin Mabs 
consistently failed to block adherence of M..... pulmonis to either untreated 
or trypsin-treated human RBCs (data not shown). Naturally infected rat 
sera blocked binding to trypsin-treated RBCs, but not to untreated RBCs 
(data not shown) . 
Identification of the M..... pulmonis Hemolysin 
The HL protein was identified as an 88.5 kDa protein by three anti-
HL Mabs using the RIP reaction (Fig. 2, lanes 1 - 3). The trypsin 
sensitivity of the hemolysin was confirmed by treating intrinsically 
radiolabeled whole cells with trypsin prior to solubilization of proteins 
in RIP buffer. This resulted in the disappearance of the 88.5 kDa 
protein from the gel (lane 4). For comparison, the radiolabeled antigen 
preparation (lane 6) and trypsin-treated preparation (lane 5) are also 
shown. 
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Table 1. Results of Mab ELISA tests and hemolysis inhibition assays. 
lC5B9* 
1C5E6 
2C3F2 
7D2Bl0 
12C3Bl 
12D2All 
11C2A5 
1B3Gl* 
1D4Gl2* 
3D3C4 
Sp.d Isoe LAg 
M 
M 
M 
M 
M 
M 
M 
R 
R 
R 
IgM +++ 
IgM +++ 
IgGl ++ 
IgGl +++ 
IgG2b ++ 
IgA ++ 
IgA ++ 
IgG2b ++ 
IgM + 
IgG2b + 
Antigena 
Try WC 
+++ + 
+++ 
nt + 
nt + 
nt + 
nt + 
+ 
++ nt 
+ nt 
nt nt 
Memb TRP 
+ + 
nt nt 
n t nt 
nt nt 
nt nt 
nt nt 
nt nt 
+ + 
+ + 
Percent Inh.b 
Mab Fab TRP 
82 
42 
14 
17 
5 
19 
0 
100 
100 
1 7 
50 1 7 
nt nt 
nt nt 
nt nt 
nt nt 
nt nt 
nt nt 
70 19 
50 11 
nt nt 
aLAg - carbonate buffer lysed antigen; Try = trypsin-treated 
antigen; WC - whole cell antigen; Memb =purified membranes; TRP -
t r ypsin -released peptides. nt - not tested. Data represents re l ative 
ELISA values: (+++) - ELISA O.D. greater than 2 . 0; (++) = 0.5 < O.D. < 
2 .0 ; (+) = 0.1 < O. D. < 0.5; (-) O. D. < 0.1. 
bnata represent percent HL inhibition as defined in text. Purified 
intact Mabs (Mab), Fab fragments (Fab), or Mabs +trypsin-released 
peptides (TRPs) were added to hemolysis assays and percent inhibition was 
determined (see Materials and Me t hods ) . 
cNumber - Mab number. (*) indicates Mabs used to identify HL by 
RIP reactions. 
dM - mouse; R - rat . 
eisotype . 
0 ... -c 
0 .. (.) -c 
C1) 
(..) ... 
C1) 
Q. 
FIGURE 1. 
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20 
0 
0 30 60 90 
Time (Min) 
Hemolysin blocking activities of rabbit and mouse hyperimmune 
antisera , nat urally i nfected rat an tisera, and rat and mouse 
Mab s. Symbols: e , positive control (no antibodies); A , 
hyperimmune rabbit antisera; O, hyperimmune mouse antisera; 
• . naturally infected rat sera; 0 , mouse Mab 1C5B9; ~ . rat 
Mab 1B3Gl. Data are presented as percent l ysis: [(0.D. Tx/ 
O. D. TC90 x 100 ] where Tx - O. D. at 0, 45 or 90 min for each 
reaction, and TC9o - O.D. control at 90 min. 
FIGURE 2. 
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1 2 3 4 s 6 
92.5 - -
69.0 -
46.0 -
30.0 -
2 1.S-
I mrnunoprec i pitati on of the !:L_ pulmonis hemolysin. Mabs 1C5B9 
(mouse, lane 1), 1B3Gl (rat, lane 2) and 1D4Gl2 (rat, lane 3) 
were used to precipitate proteins from a radiolabeled !:L_ 
pulmonis antigen preparation (lane 6). The single band in 
lanes 1 - 3 represents the !:L_ pulmonis hemolysin (88.5 kDa). 
Lanes 4 and 5 contain radiolabeled proteins from trypsin-
treated whole cells. Trypsin t r eatment of radiolabeled whole 
cells prior to i mrnunoprecipitation wi th Mab 1D4Gl2 resulted 
in the loss of the 88 . 5 kDa hemolysin from the gel (lane 4) 
and this band was also missing in the trypsin treated antigen 
preparation (lane 5). Molecular weight markers are shown on 
the left i n kilodaltons. 
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DISCUSSION 
The !:L_ pulmonis hemolysin (HL) is a unique molecule which can be 
differentiated from other mycoplasmal hemolytic activities by its 
association with an external membrane protein (22). To study this 
protein further, HL-specific Mabs were produced and used to determine its 
size (88.5 kDa, Fig. 2), and confirm its membrane location and trypsin 
sensitivity. The antigenic epitope recognized by these three Mabs 
resides on a soluble tryptic peptide, and the antigenicity of this 
fragment is retained in solution as evid~nced by the ability of TRPs to 
block anti-HL activity and their recognition in the ELISA by hemolysin 
specific Mabs. 
Mycoplasmas seem to adhere and interact with cell surfaces through 
complex mechanisms. !:L_ pneumoniae is the most extensively studied 
mycoplasma, and contains a large membrane protein as the primary mediator 
of attachment to eukaryotic cell surfaces, but a 32 kDa protein has also 
been implicated in attachment (15b). Studies of this protein, Pl, have 
shown that it contains lectin-like activity for sialic acid residues. 
Cytoadherence of !:L_ pneumoniae to hamster tracheal rings or chicken RBCs 
can be inhibited with Pl specific rabbit antisera or Mabs (18,25), but 
Mabs to lipids enhanced binding to RBCs (25). Attachment of !:L_ 
pneumoniae to glass can also be inhibited with antisera ( 13 ). 
The adherence mechanism of !:L_ pulmonis seems to be more complex, 
however, involving both specific and nonspecific activities (24). In 
order to differentiate membrane hemolysis from trypsin sensitive Type II 
adherence, attempts were made to block adherence using Mabs and various 
sera. Anti-HL Mabs failed to block Type II adherence to trypsin-treated 
human RBCs in contrast to hyperimmune rabbit sera, na turally infected rat 
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sera, and a membrane positive, HL negative Mab. This indicated that the 
activity of the anti-HL Mabs was due to specific antibody interactions 
and not to nonspecific effects arising from the blockage of binding of 
the organism to the MR.Bes. It also suggested that hemolysis and Type II 
adherence were separable properties of the M..:.. pulmonis membrane. These 
studies lend credence to the idea that binding of M..:.. pulmonis to RBCs is 
a complex multiphasic interaction (24) because antibodies failed to block 
Type I adherence to untreated RBCs (data not shown). In fact, increased 
binding was often observed supporting previous reports of increased 
binding of mycoplasmas to RBCs in the presence of specific antibodies 
(25). Further studies are required to give a better understanding of the 
differences between Types I and II adherence. 
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GENERAL SUMMARY AND DISCUSSION 
The !:L_ pulmonis hemolysin was previously shown to be a membrane-
bound , trypsin-sensitive protein whose activity was temperature 
sensitive, required a carrier molecule , and was capable of lysing 
trypsin-treated (RBC) more effectively than nontreated RBCs (52) . This 
study increases our knowledge about this molecule by showing that the 
hemolysin is 88 . 5 kDa in apparent molecular weight, remains membrane-
bound and active in membrane fragments, has unusual antigenic properties, 
and can be differentiated from Type II adherence properties . The 
molecule is capable of eliciting an immune response in infected but not 
in systemically immunized animals. In addition, antigenic epitopes are 
located in an outer tryptic fragment . 
Several differences exist between the !:L.. pulmonis hemolysin and 
other characterized bacterial hemolysins. Most notable is the membrane 
location; all but one of the bacterial hemolysins are extracellular. The 
membrane-bound hemolysin from Serratia, however, is only active in viable 
cells. In addition, none of the other bacterial hemolysins, including 
the hemolysins from Serratia, are temperature-sensitiv e or require a 
helper molecule . Finally , the observation that the !:L_ pulmonis is more 
effective in lysing trypsin-treated RBCs has not been demonstrated with 
other hemolysins . Thus , the hemolysin from !:L_ pulmonis is a unique 
molecule, with a different mechanism of action . 
These studies shed little light on the mechanism of action because 
of the peculiarity of its association with a membrane . There has been a 
suggestion of a role in cholesterol uptake (50) and this may be the 
mechanism whereby RBCs are lysed. A more defined study, which may 
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require the construction of specific mutants, is required before the 
exact mechanism is elucidated. 
Studies using this approach might proceed by purifying the protein 
using the immunoreagents generated during these studies. Purified 
protein could then be used to generate monospecific antisera for use in 
identifying the specific sequences in genomic libraries . Using 
recombinant DNA technology and recently developed methods for introduc ing 
specific mutations in !:L.. pulmonis (48b,48c), a series of mutations could 
then be constructed in the hemolysin gene. Tbe resulting mycoplasma 
mutants could be studied for phenotypic characteristics, pathogenic 
potential, etc. These mutants may also serve as suitable vaccine 
candidates. Other studies might include screening of antisera from 
acute, chronic and convalescent animals to test for the presence, 
quantity and isotype of antibodies to the hemolysin which arise during 
the course of infection . 
In conclusion, the hemolysin from !:L.. pulmonis is a unique molecule 
unrelated in characteristics and possibly mechanism of action to other 
known bacterial hemolysins. It has a possible role in the acquisition of 
cholesterol and phospholipids, and may be involved in the pathogenesis of 
MRM. The further characterization of this molecule may result in 
determining the mechanism of action and producing an effective vaccine 
against !:L.. pulmonis infection of rodent colonies . 
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